Verve Therapeutics
About Us
Why Cardiovascular Disease
Our Approach
Our Pipeline
Culture & Careers
Investors
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
In vivo CRISPR editing with no detectable genome-wide off-target mutations
Post navigation
Previous Post
Previous
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
Next Post
Next
Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing
Home
About Us
Why Cardiovascular Disease
Our Approach
Our Pipeline
Culture & Careers
Investors
►
◄ Back
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
Contact Us